P. C. Bruijnincx and P. J. Sadler, New trends for metal complexes with anticancer activity, Curr Opin Chem Biol, vol.12, pp.197-206, 2008.

M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger, and B. K. Keppler, Antitumour metal compounds: more than theme and variations, pp.183-94, 2008.

P. J. Dyson and G. Sava, Metal-based antitumour drugs in the post genomic era, pp.1929-1962, 2006.

L. Kelland, The resurgence of platinum-based cancer chemotherapy, Nat Rev Cancer, vol.7, pp.573-84, 2007.

G. Kannarkat, E. E. Lasher, and D. Schiff, Neurologic complications of chemotherapy agents, Curr Opin Neurol, vol.20, pp.719-744, 2007.

M. Markman, Toxicities of the platinum antineoplastic agents, Expert Opin Drug Saf, vol.2, pp.597-607, 2003.

C. S. Allardyce and P. J. Dyson, Ruthenium in medicine: current clinical uses and future prospects, Platinum Metals Rev, vol.45, p.62, 2001.

L. J. Anghileri, The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor, Z Krebsforsch Klin Onkol Cancer Res Clin Oncol, vol.83, pp.213-220, 1975.

T. Giraldi, G. Sava, G. Bertoli, G. Mestroni, and G. Zassinovich, Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloroplatinum(II), Cancer Res, vol.37, pp.2662-2668, 1977.

G. Sava, T. Giraldi, G. Mestroni, and G. Zassinovich, Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis -dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma, Chem Biol Interact, vol.45, pp.1-6, 1983.

B. K. Keppler, W. Balzer, and V. Seifried, Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III), Arzneimittelforschung, vol.37, pp.770-771, 1987.

G. Sava, S. Pacor, S. Zorzet, E. Alessio, and G. Mestroni, Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system, Pharmacol Res, vol.21, pp.617-645, 1989.

S. Fruhauf and W. J. Zeller, New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells, Cancer Res, vol.51, pp.2943-2951, 1991.

O. Novakova, J. Kasparkova, O. Vrana, P. M. Van-vliet, J. Reedijk et al., Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes, Biochemistry, vol.34, pp.12369-78, 1995.

R. E. Morris, R. E. Aird, M. Pdel, and S. , Inhibition of cancer cell growth by ruthenium(II) arene complexes, J Med Chem, vol.44, pp.3616-3637, 2001.

C. Scolaro, A. Bergamo, and L. Brescacin, In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes, J Med Chem, vol.48, pp.4161-71, 2005.

H. Depenbrock, S. Schmelcher, and R. Peter, Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells, Eur J Cancer, vol.33, pp.2404-2414, 1997.

A. Bergamo, B. Gava, and E. Alessio, Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity, Int J Oncol, vol.21, pp.1331-1339, 2002.

G. L. Cohen, W. R. Bauer, J. K. Barton, and S. J. Lippard, Binding of cis -and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix, Science, vol.203, pp.1014-1020, 1979.

H. Y. Mei and J. K. Barton, Tris(tetramethylphenanthroline) ruthenium(II): a chiral probe that cleaves A-DNA conformations, Proc Natl Acad Sci U S A, vol.85, pp.1339-1382, 1988.

V. Brabec, DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair, Prog Nucleic Acid Res Mol Biol, vol.71, pp.1-68, 2002.

B. M. Zeglis, V. C. Pierre, and J. K. Barton, Metallo-intercalators and metallo-insertors, Chem Commun (Camb), pp.4565-79, 2007.

C. Gaiddon, P. Jeannequin, P. Bischoff, M. Pfeffer, C. Sirlin et al., Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms, J Pharmacol Exp Ther, vol.315, pp.1403-1414, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-02360373

R. L. Hayward, Q. C. Schornagel, and R. Tente, Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175, Cancer Chemother Pharmacol, vol.55, pp.577-83, 2005.

S. Chatterjee, S. Kundu, A. Bhattacharyya, C. G. Hartinger, and P. J. Dyson, The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways, J Biol Inorg Chem, vol.13, pp.1149-55, 2008.

M. A. Jakupec, E. Reisner, and A. Eichinger, Redoxactive antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential, J Med Chem, vol.48, pp.2831-2838, 2005.

K. S. Smalley, R. Contractor, and N. K. Haass, An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells, Cancer Res, vol.67, pp.209-226, 2007.

W. H. Ang, D. Luca, A. Chapuis-bernasconi, C. , J. et al., Organometallic ruthenium inhibitors of glutathione-S -transferase P1-1 as anticancer drugs, ChemMedChem, 2007.

S. J. Dougan, A. Habtemariam, S. E. Mchale, S. Parsons, and P. J. Sadler, Catalytic organometallic anticancer complexes, Cancer Research Cancer Res, vol.105, issue.13, pp.11628-11661, 2008.

L. Leyva, C. Sirlin, and L. Rubio, Synthesis of cycloruthenated compounds as potential anticancer agents, Eur J Inorg Chem, pp.3055-66, 2007.

S. Benosman, I. Gross, and N. Clarke, Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis, Cell Death Differ, 2007.

I. Nicoletti, G. Migliorati, M. C. Pagliacci, F. Grignani, and C. Riccardi, A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry, J Immunol Methods, vol.139, pp.271-280, 1991.

I. Gross, O. Armant, and S. Benosman, Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival, Cell Death Differ, vol.14, pp.1802-1814, 2007.

D. Ord and T. Ord, Characterization of human NIPK (TRB3, SKIP3) gene activation in stressful conditions, Biochem Biophys Res Commun, vol.330, pp.210-218, 2005.

E. Selim, J. T. Frkanec, and R. Cunard, Fibrates upregulate TRB3 in lymphocytes independent of PPARa by augmenting CCAAT/enhancer-binding protein h (C/ EBPh) expression, Mol Immunol, vol.44, pp.1218-1247, 2007.

M. Ubeda and J. F. Habener, CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation, J Biol Chem, vol.278, pp.40514-40534, 2003.

A. Bruhat, C. Jousse, V. Carraro, A. M. Reimold, M. Ferrara et al., Amino acids control mammalian gene transcription: activating transcription factor 2 is essential for the amino acid responsiveness of the CHOP promoter, Mol Cell Biol, vol.20, pp.7192-204, 2000.

K. Reimers, C. Y. Choi, V. Bucan, and P. M. Vogt, The Bax Inhibitor-1 (BI-1) family in apoptosis and tumorigenesis, Curr Mol Med, vol.8, pp.148-56, 2008.

E. C. Pietsch, S. M. Sykes, S. B. Mcmahon, and M. E. Murphy, The p53 family and programmed cell death, Oncogene, vol.27, pp.6507-6528, 2008.

C. Thiriet and J. J. Hayes, Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair, Mol Cell, vol.18, pp.617-639, 2005.

A. Mandic, J. Hansson, S. Linder, and M. C. Shoshan, Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling, J Biol Chem, vol.278, pp.9100-9106, 2003.

J. Shen, X. Chen, L. Hendershot, and R. Prywes, ER stress regulation of ATF6 localization by dissociation of BiP/ GRP78 binding and unmasking of Golgi localization signals, Dev Cell, vol.3, pp.99-111, 2002.

D. Ron and P. Walter, Signal integration in the endoplasmic reticulum unfolded protein response, Nat Rev Mol Cell Biol, vol.8, pp.519-548, 2007.

S. J. Marciniak, C. Y. Yun, and S. Oyadomari, CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum, Genes Dev, vol.18, pp.3066-77, 2004.

H. Zinszner, M. Kuroda, and X. Wang, CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum, Genes Dev, vol.12, pp.982-95, 1998.

S. Oyadomari and M. Mori, Roles of CHOP/GADD153 in endoplasmic reticulum stress, Cell Death Differ, vol.11, pp.381-390, 2004.

I. N. Mungrue, J. Pagnon, O. Kohannim, P. S. Gargalovic, and A. J. Lusis, CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-3-CHOP cascade, J Immunol, vol.182, pp.466-76, 2009.

J. G. Gong, A. Costanzo, and H. Q. Yang, The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage, Nature, vol.399, pp.806-815, 1999.

S. Yang, C. Kuo, J. E. Bisi, and M. K. Kim, PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2, Nat Cell Biol, vol.4, pp.865-70, 2002.

C. J. Norbury, B. Zhivotovsky, L. Mili, M. Leyva, and . Jenny, DNA damage-induced apoptosis, Cancer Res Xiangjun Meng, vol.23, pp.5458-5466, 2004.